Armata Pharmaceuticals, Inc. — Earnings Release 2015

May 22, 2015

8-K 1 v411480_8k.htm 8-K

Field: Rule-Page

Field: /Rule-Page

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

Form 8-K

Field: Rule-Page

Field: /Rule-Page

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 19, 2015

Field: Rule-Page

Field: /Rule-Page

AMPLIPHI BIOSCIENCES CORPORATION

(Exact name of Registrant as specified in its charter)

Field: Rule-Page

Field: /Rule-Page

Washington	000-23930	91-1549568
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

800 East Leigh Street, Suite 209

Richmond, Virginia 23219

(Address of principal executive offices) (Zip code)

(804) 827-2524

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Field: Rule-Page

Field: /Rule-Page

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Field: Page; Sequence: 1

Field: /Page

Item 7.01 Regulation FD Disclosure.

On May 19, 2015, AmpliPhi Biosciences Corporation issued a press release announcing its first quarter 2015 financial results.

A copy of the press release is furnished as Exhibit 99.1 to this report

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release, dated May 19, 2015

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ David E. Bosher
David E. Bosher
Chief Financial Officer

Field: Page; Sequence: 3

Field: /Page

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release, dated May 19, 2015.

Field: Page; Sequence: 4; Options: Last

Field: /Page